The Quantum BioPharma Ltd. (QNTM) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer in the United States. Quantum BioPharma submits Form 6-K reports under the Securities Exchange Act of 1934, which include press releases, condensed consolidated interim financial statements, management’s discussion and analysis of financial condition and results of operations, material change reports, information circulars, and voting results. These documents give investors insight into the company’s biopharmaceutical activities in neurodegenerative and metabolic disorders and alcohol misuse disorders, as well as its capital markets and corporate actions.
Recent Form 6-K filings incorporate financial statements and MD&A for periods ended September 30, 2025, along with CEO and CFO certificates and related XBRL data. Other 6-Ks attach press releases covering topics such as clinical progress with Lucid-21-302 (Lucid-MS), at-the-market offering agreements, private placements, warrant expirations, and updates on the company’s digital asset portfolio. Additional filings include material change reports and management information circulars that document corporate decisions, shareholder meetings, and changes reported under Canadian securities rules but furnished to the SEC for U.S. investors.
Through these filings, users can review how Quantum BioPharma describes its lead MS program, licensing arrangements for unbuzzd , strategic investments via FSD Strategic Investments Inc., and litigation-linked contingent value rights (CVRs). The filings also reference the company’s registration statement on Form F-3, into which certain 6-K exhibits are incorporated by reference. On Stock Titan, these documents are updated from EDGAR in near real time and are accompanied by AI-powered summaries that highlight key points from each report, helping readers quickly understand financial disclosures, clinical milestones, capital structure changes, and other material information without reading every page.
Investors can use this filings page to locate Quantum BioPharma’s quarterly financial information, narrative analysis, press releases furnished as exhibits, and other regulatory documents that together outline the company’s operations, risk factors referenced in its Canadian and U.S. disclosures, and the evolution of its MS, alcohol health, and investment activities.
Malone Wealth Ventures LLC has filed a Schedule 13D/A amendment disclosing a 17% ownership stake (580,806 shares) in Quantum Biopharma. The filing reveals significant recent share accumulation through multiple transactions between June 13-20, 2025, with purchase prices ranging from $19.10 to $37.59 per share.
Key details:
- Kevin Malone serves as Advisor to Quantum Biopharma's Board of Directors
- Received 90,000 shares in total as compensation (30,000 initial grant plus 60,000 additional)
- Has sole voting power over 52,265 shares and sole dispositive power over 580,806 shares
- Shares acquired through client funds (Malone Wealth Ventures) and board advisor compensation
The filing indicates potential influence over company control, with Malone participating in discussions regarding strategic direction, financing, capitalization, and corporate governance. The advisory agreement was established on April 15, 2025, with additional RSUs available based on performance goals.